B2BROKER
19.1.2021 11:02:47 CET | Business Wire | Press release
B2Broker , a liquidity and technology provider of solutions for the crypto and Forex industry, has added a new range of features to its matching engine, B2Trader, enabling client demands to be met in record time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005197/en/
About B2Trader
B2Trader is used by many of the world's best-known exchanges, MTF Brokers, Security Exchanges, Market Makers, Spot FX Brokers and EMIs, with the job of matching an incoming market order of the user with the existing limit order of another user. The engine works 24/7 in parallel with the round-the-clock rhythm of the crypto markets without any breaks.
Matching - Tech Stack, Details, Scheme of the Module and Capacity
The order matcher is designed for crypto trading and low-latency automatic trading systems and is able to fulfill 10,000 requests per second with an average latency of 500 ms. The new matching engine uses C # ASP.NET Core programming languages for the back-end and includes a trading mechanism for matching orders, various APIs and synchronization services and databases.
API - All Details, Languages and Capacity
The stability and performance aspects of the engine now allow for the development of faster APIs. B2Broker has introduced a new API for robotic trading and public data access which handles trading and public requests much faster while positively affecting the overall system performance (trading and public API - Websocket/Rest). With new API access, users can connect directly into the matching system and operate ultra-fast trading orders or receive crypto markets data on DOMs.
Security
B2Trader incorporates a series of the latest features to provide the best possible protection from technical and fraud threats. These include an anti-throttling system, anti-spoofing protection and DDoS protection. Other security features include 2FA, adding an extra layer of security, and an IP Whitelist which puts in place a restriction to work only under a certain IP inside the admin panel.
Front End
A professional GUI meets all requirements from beginners to pro-traders. It provides a multitude of features and a high degree of customisation including adaptive colouring, easy and highly responsive navigation menu, grouping for sorting options into a more convenient structure and a customisable Dynamic User Interface with colour and font customisation which includes easy addition of widgets, workspaces for various trading styles, widgets customization and workspace arrangement.
Some recent developments include a watchlist that allows for the addition of favourite instruments to monitor percentage changes, White/Night mode, a broad variety of deposit/withdrawal methods featuring B2BinPay , IOC/FOK order settings and the availability of multiple sources of liquidity available for connection with B2Trader.
Back Office
B2Trader admin takes care of all operational options that need to be carried out by the exchange daily, delivering them in a user-friendly and sophisticated manner. The admin module allows you to manage and set up and change exchange user trading/withdrawal permissions, extract information on the history of user logins to the exchange UI, transfer history, user asset balances, information on a user's aggregate balance in indicative currency, setup commissions for the markets or particular user and more, with safety always a top priority.
SAAS AWS
B2Trader uses hosting solutions that dynamically scale resources and support the most demanding and highly loaded projects. AWS hosting offers high levels of availability, scalability and performance, requiring higher amounts of management and administration that is fully organised by B2Broker.
Third-Party Integrations
To set up and run a successful exchange business, there needs to be an equal focus on sales and marketing, compliance, deposits, withdrawals, licenses, and the regulatory framework, etc. To this end, B2Broker has integrated a variety of services that help exchanges manage all aspects effectively. These include B2BinPay, B2Core , Crystal Blockchain, Leading Fiat PSPs, SumSub, B2BX and MarksMan.
The latest features combined with external integrations further enhance B2Trader to deliver a matching engine with the ultimate in performance and functionality, while ensuring that all market participants are given the best execution.
New clients can now benefit from a discount on setup, offering more favourable pricing than 2020 due to COVID and the new market bull run.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210119005197/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom